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Abstract
Introduction
Prognosis after resection of hepatocellular carcinoma (HCC) is highly variable. Compared
to clinicopathologic factors, the use of molecular markers to predict outcome has not been
well studied. We investigated the prognostic importance of thymidylate synthase (TS) gene
expression and polymorphisms in patients after resection of HCC.
Methods
Patients who underwent complete resection of HCC for whom tissue was available were
identified. TS gene expression level and polymorphisms were determined in HCC speci-
mens. Prognostic factors were evaluated using Kaplan-Meier curves and Cox proportional
hazard models.
Results
The study included 67 patients. In univariate analysis, variables that negatively influenced
survival included TNM stage, microvascular invasion, and high TS expression. For the
high TS expression group, median survival was 54 months and 5-year actuarial survival
was 47%. For the low TS expression group, median survival was not reached and the
5-year actuarial survival was 91%. In multivariate analysis, only high TS expression
remained an independent predictor of poor survival (HR = 10.77, 95% CI 1.36–84.91;
P = 0.02). TS gene polymorphisms were not associated with TS expression or overall
survival.
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Conclusions
High TS expression predicts poor outcome after resection of HCC. Molecular markers might
be robust predictors of patient outcome after resection of HCC.
Introduction
Liver cancer is the second leading cause of cancer-related deaths globally, with an incidence of
about 850,000 new cases each year. Hepatocellular carcinoma (HCC) accounts for about
ninety percent of all cases of primary liver cancer.[1] In the United States, the incidence of
HCC has been increasing over the past two decades;[2] there were an estimated 22,620 new
cases and 18,160 deaths from HCC in 2009.[3] Overall, the 1- and 3-year survival of patients
diagnosed with HCC is 20% and 5%, respectively.[4]
The highly variable prognosis after resection of HCC has led to efforts to identify clinico-
pathologic factors that would better predict survival. Prognostic factors commonly reported
include tumor size, vascular invasion, multifocality, alpha-fetoprotein (AFP) level, Child-Pugh
class, bilirubin, and CLIP score.[5] Unlike that of clinicopathologic factors, the importance of
molecular markers in predicting outcome in patients after resection of HCC has not been well
studied.
In this study, we analyzed the prognostic relevance of thymidylate synthase (TS) mRNA
expression in HCC. TS is the target of 5-fluorouracil (5-FU), a pyrimidine anti-metabolic
agent that has been used for the treatment of gastrointestinal cancers for nearly 50 years.
Indeed, TS was the first chemotherapeutic agent evaluated for efficacy against HCC.[6] 5-FU
inhibits TS, the sole de novo source of thymidine in cells, thereby shutting down DNA synthe-
sis and inducing cell death. 5-FU by itself, or in combination with other agents, is the most
common and effective agent used for the treatment of head and neck, breast, pancreas, and
gastrointestinal tract cancers, and the response to 5-FU is at least partially related to the expres-
sion of TS.[7–10]
The mechanisms that regulate TS expression are not fully known. However, polymor-
phisms within the TS gene appear to be important determinants of the level of TS expression,
and some polymorphisms affect the probability of a response to 5-FU-based chemotherapy.
TS promoter enhancer region (TSER) 2R/3R repeat polymorphisms reflect double (2R) or tri-
ple (3R) repeats of a 28-bp sequence upstream of the TS translational start site.[10] Metastatic
colorectal and gastric cancers homozygous for the triple repeat (3R/3R) have higher TS expres-
sion than those homozygous for the double repeat (2R/R).[11, 12] Poorer response to 5-FU
occurs in patients with the 3R allele in colorectal cancer.[13] In addition, a G to C single nucle-
otide polymorphism (SNP) in the second repeat of the 3R allele has been identified. 3G-con-
taining genotypes (2R/3G, 3C/3G, 3G/3G) are associated with increased transcriptional and
mRNA translational activity in vitro and in vivo, as well as with high TS mRNA levels, poor
response to 5-FU based therapy, and poor clinical outcome.[11, 14–17] A third TS polymor-
phism is a 6-bp deletion in the 3’-UTR. Patients with colorectal cancer homozygous for the TS
3’-UTR 6-bp deletion (-6bp/-6bp) have lower TS mRNA levels than individuals homozygous
for the insertion (+6bp/+6bp).[18]
Previous studies reported high TS expression in HCC specimens compared with matched
normal liver.[19, 20] The effects of high TS expression in a cohort of Japanese patients with
HCC were inconclusive.[21] More recent studies reported the significance of TS expression
and gene polymorphisms to 5-FU based therapies and prognosis of Asian patients.[22–24]
TS expression predicts survival in HCC
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However, similar studies of patients in non-Asian countries have yet to appear. For this reason,
we evaluated TS expression in HCC from patients at the University of California San Francisco
(UCSF) who underwent complete resection, and determined the prognostic significance of
high TS expression. The frequency and impact of TS polymorphisms on TS expression and
prognosis in HCC were also investigated.
Material and methods
Patient characteristics
Sixty-seven patients underwent resection of primary HCC at UCSF from 2/09/1990 to 01/09/
2007. All specimens were from patients who underwent complete resection (R0) of their liver
tumors. No patient received 5-FU or any other systemic therapy before or after resection. The
UCSF Committee on Human Research approved the study (CHR Approval# 6172-26943-05).
Real-time PCR quantification of mRNA expression
Real-time PCR quantified relative TS gene expression in 43 HCC specimens of snap-frozen tis-
sue prepared by placing tissue in liquid nitrogen immediately after resection. Tissue samples
were homogenized in Trizol and total RNA was isolated. Total RNA was quantified by mea-
surement of absorbance at OD260 in an Eppendorf spectrophotometer.
cDNA synthesis was conducted with 1 μg total RNA using a SuperScript III first-strand syn-
thesis kit. 1 μl of cDNA synthesis mix (diluted 1:10) was dispensed in triplicate into optical
384-well plates for Taqman RT-PCR. This was mixed with Taqman Universal PCR Mastermix
with no AmpErase UNG and Taqman Gene Expression Assays in an end-volume of 10 μl. TS
PCR primer and TaqMan probes were obtained as a pre-formulated mixes from Applied Bio-
systems and used according to the company’s assays-on-demand protocol. β-actin was chosen
as an endogenous control to normalize expression data. Reactions were performed on an
Applied Biosystems ABI Prism 7900. Samples were incubated at 95˚C for 15 minutes, followed
by 40 cycles at 95˚C for 15 seconds, and 60˚C for 1 minute. In non-template control replicates
of each gene, no false positive was detected. Assays were performed in triplicate.
Taqman PCR results in an increased fluorescent signal, which correlates to the concentra-
tion of PCR amplified. When fluorescent signal intensity is plotted versus PCR cycle number,
amplification translates into a logarithmic curve which exceeds the nonspecific background
after several PCR rounds. The cycle at which the background is exceeded is defined as the
threshold cycle. Relative gene expression of TS was determined based on the threshold cycle
of the gene of interest and of the internal reference gene. Results were determined as follows:
2- (deltaCt sample- deltaCt calibrator), where deltaCt values of the calibrator and sample were deter-
mined by subtracting the Ct value of the target gene from the value of the β-actin gene.
TS genotyping
DNA was extracted from frozen or paraffin-embedded HCC tissues from 67 patients using the
QiaAmp kit. Genotyping was done using a PCR-based restriction fragment length polymor-
phism technique.[12, 16, 18]
Statistical methods
The non-parametric Mann-Whitney U test and the Kruskall-Wallis test were used to test for
differences in TS expression between two or more groups. The method of Hothorn and Lausen
was used to estimate the cut-point for TS mRNA expression that best separated low and high
gene expression groups based on log-rank statistics.[25] The maximally selected rank statistic
TS expression predicts survival in HCC
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for this cut-point was calculated using Maxstat statistical software in R language (The R Foun-
dation for Statistical Computing, Version 2.0.0, Vienna, Austria. ISBN 3-900051-00-3, URL:
http://cran.r-project.org/).
Overall survival was calculated from the date of hepatic resection to the date of death, or the
last date the patient was known to be alive. The Kaplan-Meier method estimated survival prob-
abilities, and the log-rank test compared survival distributions. Cox proportional hazards
regression analysis estimated hazard ratios, adjusting for the effect of other potential con-
founders, which were defined as clinicopathological variables whose p-value was <0.05 in the
univariate analysis (microvascular invasion and TNM stage, see Table 1). Statistical
Table 1. Univariate analyses of clinicopathological variables as predictors of overall survival after resection for hepatocellular carcinoma (n = 67).
Variable n Median Survival (months) 5-year OS (%) p-value (Log-rank)
1.Gender 0.3
Males 50 61 53
Females 17 161 63
2.Age 0.49
< 60 years 24 40 46
�60 years 43 71 60
3.TNM Stage (AJCC) 0.02
I 28 99 72
II 20 38 46
III 19 22 38
4. Cirrhosis of the liver 0.48
Present 37 99 56
Absent 30 62 55
5.Histologic Grade 0.48
Well 29 92 57
Moderate 31 62 49
Poor 7 22 25
6.Tumor Number 0.13
Single 43 92 67
Multiple 24 31 40
7.Tumor Size (largest size if multi) 0.3
<5 cms 24 99 54
�5 cms 43 62 55
8. Microvascular invasion 0.002
Present 23 30 32
Absent 44 92 66
9. Surgical margin 0.93
<1 cm 33 71 51
� 1 cm 34 62 59
10. AFP level (ng/ml) 0.98
<15 23 61 58
16 to <2000 25 161 56
� 2000 11 92 58
11. Hepatitis status 0.26
HBs antigen(+) 25 99 68
anti-HCV antibody (+) 11 43 40
Negative 28 62 50
https://doi.org/10.1371/journal.pone.0219469.t001
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significance was set at a P value < 0.05. Analyses were carried out using SAS Statistical Soft-
ware version 9.1.
Results
Patient and tumor characteristics
Demographic and clinicopathologic characteristics of the patients included in this study are in
Table 1. The mean and median age of patients was 64 and 67 years, respectively (range, 26–
84), and 75% were male. According to AJCC TNM staging, 28 (42%) patients were stage I, 20
(30%) stage II, and 19 (28%) stage III. Most (55%) patients had evidence of liver cirrhosis, and
most (64%) had single tumors. All patients underwent an R0 resection. The surgical margin
was< 1 cm in 33 (49%) and� 1 cm in 34 (51%) patients.
Long-term follow-up and factors influencing survival after hepatectomy
Follow-up with a median duration of 44 months (range, 0.3–157) was available for all surviving
patients. The overall median survival of patients was 71 months. Overall, five- and 10-year actu-
arial survival rates were 57% and 37%, respectively. Multiple variables were evaluated by univar-
iate analysis to determine their impact on survival in the 67 patients who underwent resection
of HCC (Table 1). Variables that did not influence survival included age, gender, presence of
cirrhosis, histological grade, tumor number, tumor size, surgical margin (< 1 cm vs.� 1 cm),
AFP level, and hepatitis status. Variables that negatively influenced survival included TNM
stage, the presence of microvascular invasion, and high TS expression (Table 2).
TS mRNA expression was quantified by RT-PCR of tumor specimens from 44 HCC cases.
Data was available for 43 of the 44 cases, because one sample failed to amplify. The range and
median of TS mRNA expression was 0.01–1.0 and 0.22, respectively. A cut point of 0.12 was
calculated using Maxstat. Fig 1A shows the segregation of the patient mRNAs into high and
low thymidylate synthase expression groups; this allowed us to plot patient survival as a func-
tion of TS expression in the form a Kaplan-Meier plot (Fig 1B). The median and 5-year overall
survival were significantly higher for the group with TS mRNA expression below the cut point
(low TS group) than for the group with TS expression above the cut point (high TS group).
Although median overall survival was not reached for the low TS group, their 91% 5-year actu-
arial survival compared favorably, and with very high statistical significance, to a 54-month
median and 47% 5-year actuarial survival for the high TS expression group (Fig 1B; P = 0.04).
Multivariate analysis, using a Cox proportional hazards model, determined which of the
variables that were significant in the univariate analysis were independent predictors of sur-
vival (Table 2). Only high TS expression (HR = 10.77, 95% CI 1.36–84.91; P = 0.02) remained
an independent predictor of worse survival, when adjusted for microvascular invasion and
TNM stage.
Frequency of TS polymorphisms in hepatocellular carcinoma
In some cancers, TS polymorphisms affect TS expression.[10] However, the frequencies of TS
polymorphisms in HCC and their association with alterations of TS gene expression have not
Table 2. Multivariate analysis by cox regression.
Variable Hazard Ratio 95% Confidence Interval p-value
1. TS gene expression (Low vs. High) 10.77 1.36–84.91 0.02
2. Microvascular invasion (Presence vs Absence) 2.27 0.87–5.94 0.095
3. TNM stage (I vs. II vs. III) 1.59 0.86–2.95 0.1421
https://doi.org/10.1371/journal.pone.0219469.t002
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been studied in patients comparable to that studied here. Therefore, we investigated the fre-
quencies of the TSER 2R/3R, TSER 3R G/C, and TS 3’-UTR 6-bp deletion polymorphisms in
67 HCC samples.
The TSER 2R/3R repeat polymorphism reflects double (2R) or triple (3R) repeats of a 28-bp
sequence upstream of the TS translational start site. We observed the following allelic frequen-
cies of TSER 2R/3R repeat polymorphisms: 2R/2R (5%), 2R/3R (43%), and 3R/3R (52%). The
TSER 3R G/C polymorphism is a G-to-C single nucleotide polymorphism (SNP) in the sec-
ond repeat of the 3R allele. We detected the TSER 3R G/C SNP in 48.5% of HCC samples. A
third TS gene polymorphism is a 6-bp deletion in the 3’-UTR. We found that 80.6% of HCC
samples contained the TS 3’-UTR 6-bp deletion with the following frequencies: +6bp/+6bp
(19.4%), +6bp/-6bp (46.3%), and -6bp/-6bp (34.3%).
TS polymorphisms and gene expression levels
In other cancers, TS polymorphisms influence TS mRNA and protein expression. Evaluation
of the effect of TSER 2R/3R repeat polymorphisms on TS gene expression in metastatic colo-
rectal cancer reveals that those homozygous for the triple repeat (3R/3R) have higher TS
expression than those homozygous for the double repeat (2R/R). The TSER 3R G/C SNP
appears to diminish TS transcription. Patients with colorectal cancer homozygous for the TS
3’-UTR 6-bp deletion (-6bp/-6bp) have lower TS mRNA levels than individuals homozygous
for the insertion (+6bp/+6bp). Whether TS polymorphisms affect TS expression in HCC is
unknown, leading us to test for such a relationship.
We assayed TS gene expression in HCC samples from 43 patients. Median TS mRNA
expression did not differ between patients homozygous for the triple repeat (3R/3R) compared
to those with the 2R/2R or the 2R/3R genotype (Table 3; P = 0.32). In addition, median TS
mRNA levels in HCC patients with the TSER 3R G/C SNP did not differ from those without it
(Table 3; P = 0.53). Finally, median TS mRNA levels did not differ between patients homozy-
gous for the TS 3’-UTR 6-bp insertion (+6bp/+6bp) and patients heterozygous (+6bp/-6bp) or
homozygous (-6bp/-6bp) for the deletion (Table 3; P = 0.61). None of the clinicopathologic
Fig 1. Kaplan Meier plot of patient survival. A. High and low patient TS mRNA levels defined by Maxstat. B. Kaplan Meier plot of patient survival based on
mRNA expression characterizes overall survival as a function of TS mRNA levels assayed by qRT-PCR and dichotomized by maximum rank statistics
(cutpoint = 0.12), HCC Resection Patients (n = 43).
https://doi.org/10.1371/journal.pone.0219469.g001
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variables were associated with the level of TS gene expression or the presence of the TS poly-
morphisms (results not shown).
TS polymorphisms and clinical outcome in hepatocellular carcinoma
In patients with colorectal cancer, TS polymorphisms predict response to 5-FU-based chemo-
therapy and influence survival.[10] Whether TS polymorphisms are associated with overall
survival in patients after resection of HCC who did not receive adjuvant therapy is not known.
In this study, repeats of a 28-bp sequence in the 5’UTR, a G/C SNP in the 5’UTR enhancer
region, and a 6-bp deletion in the TS 3’UTR were genotyped in 67 HCC cases and their rela-
tionship to patient survival was evaluated. Overall survival did not differ among the 2R/2R,
2R/3R, and 3R/3R genotypes (P = 0.59)(Fig 2A), nor did overall survival differ in patients with
or without the TSER 3R G/C SNP (P = 0.26)(Fig 2B). The relationship of 6-bp deletions in the
3’UTR of TS to patient survival was also evaluated. Median survival was not reached for the
insertion group and was 61 months for the deletion group. The 5-year survival rates were 67%
and 52%, respectively (Fig 2C). Overall survival did not differ among patients with the TS 3’-
UTR 6-bp insertion (+6bp/+6bp) compared to those heterozygous (+6bp/-6bp) or homozy-
gous (-6bp/-6bp) for the deletion (P = 0.11). Finally, we tested for a relationship of combined
genotypes to overall survival (Fig 2D). The median survival for the low 5’UTR/high 3’UTR
subgroup was not reached. Median survival was 62 months for the low 5’UTR/low 3’UTR
subgroup, 54 months for the high 5’UTR/low 3’UTR subgroup, and 38 months for the high
5’UTR/high 3’UTR group. The 5-year survival rate was 80% for the low 5’UTR/high 3’UTR
group, 60% for the low 5’UTR/low 3’UTR subgroup, and 46% for the high 5’UTR/low 3’UTR.
There were no 5-year survivors for the high 5’UTR/high 3’UTR subgroup. The differences in 5
year survival for the combined genotypes did not reach statistical significance, but may suggest
a trend.
Based on in vivo studies, carriers of the TS 5’UTR 2R/2R, 2R/3C, and 3C/3C polymor-
phisms have been classified as putative low TS genotypes, whereas those with 2R/3G, 3C/3G
and 3G/3G have been classified as putative high TS genotypes. We compared the actuarial sur-
vival rates of these groups, and found that the median and 5-year overall survival rates were 92
months and 66%, respectively, for the low TS group, compared to 54 months and 46% for the
high TS genotype; however, this difference was not statistically significant (p = 0.19).
Discussion
We have shown that TS expression predicts survival in patients after resection of HCC.
Patients bearing HCC tumors expressing high levels of TS had poorer overall survival. Impor-
tantly, although HCC specimens express high TS levels compared with matched normal liver,
[19, 20] this is the first study to demonstrate an association between high TS expression and
poor outcome in patients after resection of HCC. TS is a predictive and prognostic marker in
Table 3. Association between TS gene expression levels and polymorphisms in the 5’UTR and 3’UTR.
5’UTR genotype
Median (range)
p-value 3’UTR genotype
Median (range)
p-value
3R/3R 2R/2R-2R/3R ins/ins ins/del, del/del
0.17 (0.06–1.00) 0.29 (0.01–1.00) 0.34 0.16 (0.04–0.70) 0.23 (0.01–1.00) 0.4
3RG Non-3RG
0.23 (0.01–1.00) 0.16 (0.06–1.00) 0.51
https://doi.org/10.1371/journal.pone.0219469.t003
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PLOS ONE | https://doi.org/10.1371/journal.pone.0219469 July 10, 2019 7 / 13
colorectal, gastric, and other tumors.[26–28] Our findings suggest that TS expression may
have prognostic significance in patients undergoing complete resection of HCC.
In contrast to our findings, Nii et al. found no significant difference in overall survival in
patients with high versus low TS mRNA expression in HCC, although there was a “tendency
of better prognosis” in the high TS group.[21] Moreover, Okano et al. found no significant dif-
ference in overall survival time between patients with high and low levels of TS.[22] There are
important differences between those studies and ours. Nii et al. and Okano et al. segregated
patients into high and low expression groups based on the median values of TS mRNA expres-
sion, an arbitrary method. We used maximally selected log-rank statistics to identify the opti-
mal cutoffs that actually separated tumors into high and low TS mRNA expression groups.
Thus, we used a better statistical method to identify the separation of resection patients into
two groups with different overall survival. Future studies may reveal that further sub-stratifica-
tion based on relative TS mRNA expression levels has even more prognostic significance
than a simple high vs low TS mRNA level. Another difference is that we isolated mRNA from
snap-frozen samples, whereas Nii et al and Okano et al isolated mRNA from formalin-fixed,
Fig 2. (A) Overall Survival by 5’UTR enhancer region polymorphisms, HCC Resection patients (n = 67) (B) Overall Survival as a function of TS 5’UTR G/C SNP
genotypes HCC Resection Patients (n = 67) (C) Overall Survival as a function of TS 3’UTR genotypes HCC Resection Patients (n = 67) (D) Overall Survival by TS
combined 5’UTR/ 3’UTR polymorphisms, HCC Resection Group (n = 67); Low 5’UTR = 2R/2R + 2R/3C + 3C/3C; Low 3’UTR = +6bp/-6bp + -6bp/-6bp; High
5’UTR = 3G/3G + 3G/3C + 2/3G; High 3’UTR = +6bp/+6bp.
https://doi.org/10.1371/journal.pone.0219469.g002
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paraffin-embedded specimens in which mRNA may be susceptible to degradation by ribonu-
cleases. Finally, the Nii and Okano studies were based on patients who underwent liver resec-
tion in Japan, whereas our findings are based on patients in the United States. The patient
populations in these studies likely differed with respect to ethnicity and environmental expo-
sures. The frequency of TS polymorphisms varies among ethnic populations,[10] and it is
possible that TS expression, and the significance of polymorphisms to outcome, might vary
between different patient populations.
Because TS is the target of 5-FU, many studies on the pharmacogenomics of TS sought to
identify patients likely to respond to 5-FU and experience better survival.[10] Our findings
suggest that for HCC, TS expression is an independent prognostic factor irrespective of treat-
ment with 5-FU, as shown for other cancers.[29–34] Studies have shown that TS protein and
mRNA levels are higher in cervical, breast, kidney, bladder, lung, and gastrointestinal tumors
than in their normal counterparts, and high TS expression is associated with poor prognosis
irrespective of 5-FU treatment.[29–39] The mechanism by which TS contributes to poor out-
come in patients with HCC is unclear. However, TS plays a role in DNA synthesis and repair,
derangements of which can promote oncogenesis. In addition, TS overexpression in mice pro-
motes hyperplasia and adenoma formation in the endocrine pancreas.[40, 41] Tumors with
elevated TS undergo more active cellular proliferation, which is associated with tumor inva-
siveness and metastasis.[29, 33, 37] Our results suggest that TS may play a role in HCC tumor
progression.
We found no statistically significant association of an individual polymorphism with
intra-tumoral TS expression or overall survival after resection of HCC. The possibility of
three different polymorphisms complicates efforts to understand the effect of each variant
on TS expression and outcome. Indeed, only a few studies in other cancers performed haplo-
type analysis of the three polymorphisms, as done here. In one such study, gastric cancer
patients who underwent complete resection and received adjuvant 5-FU therapy were
grouped into high (3G/2C, 3G/3C, 3G/3G, +6bp/+6bp) or low (2R/2R, 2R/3C, 3C/3C,
+6bp/-6bp, -6bp/-6bp) expression genotypes.[11] Patients with high expression genotypes,
or with at least one high expression allele, had significantly worse overall survival. Our simi-
lar analysis showed no difference in overall survival of patients after resection of HCC. How-
ever, as with gastric and colon cancers, the absence of a G/C SNP in the second repeat of the
3R allele, the non-3RG genotype, had a better long-term outcome, though this was not statis-
tically significant. This finding, and other studies that reported better survival in gastric and
advanced colorectal cancer was associated with better overall response to 5-FU based ther-
apy for non-3RG patients, leads us to speculate that a similar relationship might be found in
HCC.
Our results do not establish a relationship between 5’UTR polymorphisms and the expres-
sion level of TS mRNA in HCC. Some groups have associated the 3R/3R genotype with higher
TS mRNA expression compared to 2R/2R or 2R/3R genotypes[17]; others found no such rela-
tionship, but did find that cancer tissues with the 3R/3R genotype had higher expression of TS
protein than those with the 2R/3R genotype.[42] These results, together our observations, sug-
gest that TS genotyping, without determination of TS mRNA and protein expression levels,
may be insufficient to predict patient responses to 5-FU-based chemotherapy.
We found lower median TS mRNA expression for the non-3RG group than for the 3RG
group in HCC, although this was not statistically significant. The polymorphism may consist
of two (2R) or three (3R) repeats of the 28-bp sequence.[16, 17] The 3R genotype has been
associated with higher TS mRNA and protein expression than the 2R genotype. Two USF fam-
ily E-box consensus elements are in the tandem repeats of the 3R genotype, whereas only one
is in the 2R genotype.[18] These elements bind USF proteins with the additional element in
TS expression predicts survival in HCC
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the 3R genotype conferring greater transcriptional activity than the 2R genotype, which may
explain the higher TS mRNA expression observed in the 3RG compared to the 2RG group.
In some cancers, –6bp/-6bp and the –6bp/+6bp polymorphisms associate with low TS gene
expression, whereas the +6bp/+6bp polymorphisms associate with high TS expression. Contrary
to reports that the 6bp insertion genotype predicts shorter overall survival than the 6bp deletion
group,[43, 44] in our study, outcomes tended to be better for the 6bp insertion group. This
could be attributed to linkage disequilibrium between the 6bp insertion group and the non-3RG
group. We found significant predominance of 6bp insertion cases in the non-3RG compared to
the 3RG group (75% vs. 25% respectively; p = 0.05), which is similar to observations made in
studies of esophageal [27] and rectal cancer.[45] Thus, it is difficult to ascertain if the effect on
outcome can be ascribed to the 3’UTR polymorphism or the non-3RG genotype, which tended
to have a better outcome than the 3RG group. The association of the 3’UTR polymorphism with
the non-3RG group may also explain why median TS mRNA levels in the 6bp insertion group
are lower than in the deletion group, in contrast to reports that the 6 bp insertion at nucleotide
1494 in the 3’UTR is associated with high TS gene expression. The 6 bp deletion in the 3’UTR
has been associated with decreased mRNA instability and lower tumor TS expression.[18, 45]
There are limitations to this study, which is a retrospective analysis from a single institution,
and subject to selection and referral bias. This study involved a discrete number of patients,
making it possible that unrecognized or unique genetic characteristics may have limited its
capacity to uncover some associations. For example, the frequency of TS polymorphisms varies
among ethnic populations, which undermines attempts to study their effect on TS gene expres-
sion and prognosis.[10] Nevertheless, our analysis did identify AJCC TNM stage (which
combines characteristics of tumor size, tumor number, vascular invasion, direct invasion, per-
foration of visceral peritoneum, and regional lymph nodes), microvascular invasion, and high
TS expression as prognostic factors in HCC—the first two being important pathologic factors
described previously.[46, 47] In this cohort, the size of the surgical margin did not predict
overall survival as described previously.[48]
Conclusions
The highly variable prognosis after resection of HCC has led to efforts to identify clinicopatho-
logic factors that permit better prediction of survival.[3, 49] Because the optimal management
of patients with HCC remains controversial, identifying patients at risk for a poor outcome
will be essential for proper stratification in future clinical trials.[50] Prognostic factors com-
monly reported include tumor size, vascular invasion, multifocality, alpha-fetoprotein (AFP)
level, Child-Pugh class, bilirubin, and CLIP score.[47] However, the importance of molecular
markers in predicting outcome in patients after resection of HCC has not been well studied.
In this context, our study is valuable because it shows that TS gene expression may be an inde-
pendent predictor of survival in patients after resection of HCC. This finding suggests the
importance of molecular markers, in addition to pathologic staging, in HCC. Future studies
involving global gene expression analysis with the relevant clinical data are necessary to iden-
tify which genes are the best markers of HCC prognosis.
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